HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups

A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing the already limited funding opportunities available for startups.

By FierceBiotech · Apr 17, 2026 · via FierceBiotech
Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups

Image: FierceBiotech

Tags
moneyformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Big Pharma’s M&A Jag Freezes Biotech IPO Window
MoneyBriefing
Big Pharma’s M&A Jag Freezes Biotech IPO Window
Seven pharma takeovers over $1B each in late March, totaling $29B, may have sidelined would‑be biotech IPOs af…
Apr 17, 2026
Abbott lowers EPS guidance on Exact Sciences buy as shares slide
MoneyFierceBiotech ↗
Abbott lowers EPS guidance on Exact Sciences buy as shares slide
Abbott's first-quarter numbers reflect is operational complexity.…
Apr 17, 2026
Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors
MoneyFierceBiotech ↗
Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors
Terremoto Biosciences has spelt out how the California biotech will use a $108 million series C round to conti…
Apr 17, 2026